Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? - Wikidata - awgldk - TriplyDB

Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?

Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?

http://www.wikidata.org/entity/Q34065128

about

Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions Safety of chemotherapeutic infusion or chemoembolization for hepatocellular carcinoma supplied exclusively by the cystic artery.Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.Hong Kong consensus recommendations on the management of hepatocellular carcinoma.Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control.Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth.Intermediate hepatocellular carcinoma: current treatments and future perspectives.Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion.Locoregional and systemic therapy for hepatocellular carcinoma.Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation.ADCtotal ratio and D ratio derived from intravoxel incoherent motion early after TACE are independent predictors for survival in hepatocellular carcinoma.Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma.Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization.Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation.Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model.Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study.Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study.Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma.Successful living donor liver transplantation between septuagenarians.The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma

P2860

Q26743666-6F8B09B4-8861-4262-BD6B-041E0647C395 Q27007847-B3299F08-B04F-4AE0-995B-F65954A1101C Q33162177-95FAA59C-0A0E-479F-BBBD-560B6AA2BA80 Q33658301-1723FBAC-AB9E-4EAA-8C01-44A3C5AF65E1 Q35073497-1FABB850-3E76-4ACA-8D46-7628B8DCFF38 Q35631295-133E5DF7-5673-45AA-A86D-E48CAA14B889 Q36296750-E549C02A-F27A-499D-AD81-B71121BCFC35 Q36416250-22FDB958-313C-40F2-B662-895B35183BB4 Q36528048-A2A4E5E3-8BD5-4FFB-A9D0-87B106E04A75 Q37432022-CA768EE8-6B28-4C9A-81F2-0F3BF5C2EBE8 Q37580211-B2461DDE-9F1B-4E67-891B-7EAC0EE12C27 Q38110203-01800A35-DAB3-4527-BFE5-2E9ED2A66247 Q38265024-A6382F9F-3FB4-4792-8E58-3EA16D87DC0F Q38590448-16605235-72BC-4860-B205-2EF372D29948 Q38686790-0DFAEE04-3CA2-414A-9AC0-26E20BAD5C7A Q38792625-9EDB4646-D3E4-4540-B97F-983EC95C3766 Q39169884-631D80D3-3D52-46AD-B760-76F62908DBD8 Q40333754-1E0D0E6C-B85B-4E0B-964D-91221918C5FC Q40443863-348DEA64-053D-47C8-BA71-5DB3A6C5480F Q40593373-E60F74AD-C6E3-40A8-A2C6-01322A4B61EC Q41235807-EB4D9A3A-1F67-408A-A9B8-8151663C8912 Q47140537-CBBA0B2B-1B5E-4969-8A58-13DB96F9D5F0 Q48189816-E1153E8C-05AD-49AC-A49B-015DD42F603E Q49608357-37D2A0EB-43CF-446A-9C9D-F065BD17FF5B Q49996776-C6C1ADFC-1D8A-4D7D-8C47-FE8EC0D85C0D Q50100582-06176390-43E3-47A7-B0E2-0BCEA85A8961 Q51105877-CCEA7E82-8D6B-4D22-A702-6B98F67FB836 Q58556314-21B359E1-6E29-4737-B39E-8C1044A1ED13

P2860

Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?

http://www.wikidata.org/entity/Q34065128

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Lack of response after initial ...... ilure of subsequent treatment?

@ast

Lack of response after initial ...... ilure of subsequent treatment?

@en

Lack of response after initial ...... ilure of subsequent treatment?

@nl

type

label

Lack of response after initial ...... ilure of subsequent treatment?

@ast

Lack of response after initial ...... ilure of subsequent treatment?

@en

Lack of response after initial ...... ilure of subsequent treatment?

@nl

prefLabel

Lack of response after initial ...... ilure of subsequent treatment?

@ast

Lack of response after initial ...... ilure of subsequent treatment?

@en

Lack of response after initial ...... ilure of subsequent treatment?

@nl

P1433

Q34065128-E2FD30BC-CF50-4ECD-83C7-9C6B3165C81F

P1476

Q34065128-0EBD09FA-9F3E-4F93-BB35-0AAB986DAB45

P2093

Q34065128-02A353B2-391C-4A88-A58C-09D452D64986

Q34065128-1861BC7B-F68A-4255-BF9E-64B0EBF4C162

Q34065128-3A322F4A-5BA2-4E38-A3B7-8922B4FB76F8

Q34065128-5B936253-CC13-47C5-B561-BCEF5D4133A9

Q34065128-6F6C7217-8D22-4090-B225-CFDE24484025

Q34065128-795DDB29-4A44-4C11-80AB-7CBC38FC0ED6

Q34065128-85E5B258-56A0-40CC-AB73-0ED245314320

Q34065128-9098C736-6F57-4883-9B6E-5F5EBBBE806E

Q34065128-DFE4D9E7-E1B9-4C1E-B504-C0D4A19F31CB

P2860

Q34065128-2916F8A6-5006-4E11-AC89-9AFC1404E149

Q34065128-59EC0D2E-03A3-454F-A6ED-CBDFF07911FA

Q34065128-603E82FA-947C-4035-B341-AF65E76D700E

Q34065128-8E92A2A5-D8F9-46D8-904B-41128AC13DEF

Q34065128-9DC34333-79B5-4858-A38F-54A636D38792

Q34065128-A455C4E8-C386-487F-9FAE-A768A6BBF01E

Q34065128-AD479B71-85D3-491B-9275-B75B782502CE

Q34065128-B0325353-4B37-4925-B7CF-C093C77FE5DF

Q34065128-B8F0D52A-AAD8-4FDE-AB56-61BCBDEE17CB

Q34065128-CE2ACAE7-041D-45F0-A26A-3BF1FA0C70A2

P304

Q34065128-C1C0D0BA-F36C-4721-ACCA-18ADDB664F82

P31

Q34065128-1820EA3F-5AD8-448A-85FD-2EAD32DF4A63

P356

Q34065128-608A2564-DEE6-4FB7-A033-80573139D66F

P407

Q34065128-652C1D7F-3399-4CFF-9860-D6FF8ECE1494

P433

Q34065128-0FC0AE06-E56F-43E5-A59D-9232804AADB8

P478

Q34065128-C8C786CC-93ED-4E70-A4A3-3190921DB851

P577

Q34065128-94B55FFD-CB58-45B3-A14E-1F6ABD22E725

P698

Q34065128-09C9D049-7760-44C0-95CC-A2067E02FA24

P932

Q34065128-64FE0EA8-70A3-4B60-8B21-25557210AAEF

P356

RADIOL.12112264

P1433

P1476

Lack of response after initial ...... ilure of subsequent treatment?

@en

P2093

Andrew Hines-Peralta

http://www.w3.org/2001/XMLSchema#string

Christos Georgiades

http://www.w3.org/2001/XMLSchema#string

Constantine Frangakis

http://www.w3.org/2001/XMLSchema#string

Eleni Liapi

http://www.w3.org/2001/XMLSchema#string

Ihab Kamel

http://www.w3.org/2001/XMLSchema#string

Jean-François Geschwind

http://www.w3.org/2001/XMLSchema#string

Kelvin Hong

http://www.w3.org/2001/XMLSchema#string

Neil Harrison

http://www.w3.org/2001/XMLSchema#string

Zhenke Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.

Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres.

P304

115-123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1148/RADIOL.12112264

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

265

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22891361

http://www.w3.org/2001/XMLSchema#string

P932

4137783

http://www.w3.org/2001/XMLSchema#string